Sumitomo Mitsui Trust Group Inc. Purchases 3,000 Shares of Jazz Pharmaceuticals PLC $JAZZ

Sumitomo Mitsui Trust Group Inc. grew its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 83.3% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,600 shares of the specialty pharmaceutical company’s stock after buying an additional 3,000 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Jazz Pharmaceuticals were worth $1,248,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Cardinal Capital Management increased its position in shares of Jazz Pharmaceuticals by 0.5% during the fourth quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock valued at $2,471,000 after acquiring an additional 66 shares during the last quarter. UMB Bank n.a. grew its stake in Jazz Pharmaceuticals by 12.6% in the 4th quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock valued at $123,000 after purchasing an additional 81 shares during the period. Pinnacle Associates Ltd. increased its position in shares of Jazz Pharmaceuticals by 0.7% during the 4th quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock valued at $1,905,000 after purchasing an additional 83 shares during the last quarter. Fifth Third Wealth Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 4.4% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 1,996 shares of the specialty pharmaceutical company’s stock worth $377,000 after purchasing an additional 85 shares during the period. Finally, Root Financial Partners LLC raised its stake in shares of Jazz Pharmaceuticals by 42.8% during the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock worth $56,000 after purchasing an additional 89 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Up 0.5%

JAZZ opened at $239.32 on Thursday. Jazz Pharmaceuticals PLC has a 12 month low of $105.00 and a 12 month high of $250.49. The company has a market cap of $15.03 billion, a PE ratio of -11,960.02, a price-to-earnings-growth ratio of 0.21 and a beta of 0.32. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95. The company has a 50 day moving average of $234.37 and a 200 day moving average of $199.59.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The firm had revenue of $1.07 billion for the quarter. On average, sell-side analysts expect that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 1,200 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total value of $278,196.00. Following the completion of the transaction, the executive vice president owned 51,549 shares in the company, valued at $11,950,604.67. This trade represents a 2.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Rick E. Winningham sold 2,741 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $241.57, for a total value of $662,143.37. Following the transaction, the director directly owned 9,567 shares of the company’s stock, valued at $2,311,100.19. The trade was a 22.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 13,098 shares of company stock worth $3,131,906 in the last three months. 4.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on JAZZ. Truist Financial decreased their price objective on shares of Jazz Pharmaceuticals from $256.00 to $254.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Bank of America increased their target price on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Morgan Stanley reaffirmed an “overweight” rating and issued a $245.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, May 7th. TD Cowen increased their price objective on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Finally, Barclays raised their target price on Jazz Pharmaceuticals from $253.00 to $260.00 and gave the stock an “overweight” rating in a research report on Tuesday. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $254.47.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.